Incretin Atlas › Trials › GLORY-2
GLORY-2
Mazdutide · obesity
Design
- Molecule(s)
- Mazdutide
- Population
- obesity
- Official title
- A Study of IBI362 9 mg in Chinese Adults With Obesity
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Phase
- 3
- Registry status
- unknown · 2023-12 → 2025-06
- Participants
- 462
- Duration
- 60 weeks
- Registry
- NCT06164873
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| mazdutide 9 mg | obesity china | 60 | — | −18.6 % vs −3.0 % Δ −15.5 pp | −16.6 % vs −1.5 % Δ −15.1 pp | — | 2.9 vs 0.0 | 13.0 vs 5.2 | 46.9 vs 3.2 | 53.1 vs 1.3 | 7.2 vs 5.2 | −9.8 vs −0.2 | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- mazdutide 9 mg: Primary end point at week 60. Any-reason discontinuation computed from the completed-treatment counts (denominator 307 treated). HbA1c in the supplement only.
Verbatim quotes from the source (8)
- mazdutide 9 mg · weight_eff · Results, Coprimary Outcomes, paragraph 1 (eTable 1 in Supple
the mean percentage change in body weight from baseline to week 60 was -18.55% (95% CI, -19.78% to -17.31%) in the mazdutide group vs -3.02% (95% CI, -4.72% to -1.31%) in the placebo group
- mazdutide 9 mg · weight_tp · Table 2; Results, Coprimary Outcomes, paragraph 1
mean percentage change in body weight from baseline to week 60 was -16.65% (95% CI, -18.19% to -15.12%) in the mazdutide group vs -1.50% (95% CI, -3.43% to 0.43%) in the placebo group
- mazdutide 9 mg · ae_dc · Table 3
| Any that led to treatment discontinuation | 9 (2.9) | 0 | 2.9 (0.5 to 5.5) |
- mazdutide 9 mg · disc_any · Results, Participants; Figure 1
89.6% of participants (267 [87.0%] in the mazdutide group vs 146 [94.8%] in the placebo group) completed the treatment
- mazdutide 9 mg · nausea · Table 3
| Nausea | 144 (46.9) | 5 (3.2) | 43.7 (37.1 to 49.7) |
- mazdutide 9 mg · vomiting · Table 3
| Vomiting | 163 (53.1) | 2 (1.3) | 51.8 (45.7 to 57.5) |
- mazdutide 9 mg · sae · Table 3
| Serious adverse eventsa | 22 (7.2) | 8 (5.2) | 2.0 (-3.3 to 6.3) |
- mazdutide 9 mg · sbp · Results, Key Secondary Outcomes, paragraph 2; Table 2 (garbl
systolic blood pressure was -9.80 mm Hg (95% CI, -11.37 to -8.23 mm Hg) in the mazdutide group vs -0.23 mm Hg (95% CI, -2.13 to 1.67 mm Hg) in the placebo group
Primary sources
- Gao L, Jiang H, Cai H, Tian J, Shi B, Qiu W, et al. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA. 2026;336(5):377-388. PMID: 42251595.
- ClinicalTrials.gov NCT06164873
How to cite this page
Medical Adviser's Group. Incretin Atlas: GLORY-2. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/glory-2/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.